Basic Information
| LncRNA/CircRNA Name | H19 |
| Synonyms | H19, ASM, ASM1, BWS, D11S813E, LINC00008, NCRNA00008, WT2 |
| Region | GRCh38_11:1995176-2001470 |
| Ensemble | ENSG00000130600 |
| Refseq | NR_002196 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | thyroid cancer |
| ICD-0-3 | C73.9 |
| Methods | qPCR, Western blot, other |
| Sample | TC tissues and cell lines (FTC-133 and TPC-1) |
| Expression Pattern | up-regulated |
| Function Description | The results indicated that H19 was upregulated in TC tissues. Silencing of H19 inhibited the cell viability and promoted apoptosis of FTC-133 and TPC-1 TC cells, accompanied by an increased expression of B-cell lymphoma 2 (Bcl-2)-associated X protein and caspase 3, and repressed expression of Bcl-2. The results of western blot analysis suggested that the levels of phosphorylated phosphoinositide-3 kinase (PI3K) and phosphorylated AKT were attenuated by H19 silencing. These results suggest that lncRNA H19 exerts an oncogenic function in TC, in part through the PI3K/AKT pathway. |
| Pubmed ID | 31410148 |
| Year | 2019 |
| Title | Long Non-Coding RNA H19 Knockdown Inhibits the Cell Viability and Promotes Apoptosis of Thyroid Cancer Cells Through Regulating the PI3K/AKT Pathway |
External Links
| Links for H19 | GenBank HGNC NONCODE |
| Links for thyroid cancer | OMIM COSMIC |